Exciting news (see attached Press Release), as Pregenen has been acquired by bluebird bio, Inc. (Nasdaq: BLUE), a public gene therapy company based in the Boston area.
http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=1943834&highlight=
Pregenen designs and engineers molecules critical to a new generation of cell-based therapies for unmet medical needs.
We work with our partners to apply our tools, services and reagents to increase the reliability, efficacy and safety of a new wave of therapies harnessing the specificity and functional power of molecules and cells produced by the body.
Our approach is based on proprietary methods, reagents and software tools we have developed or licensed from leading laboratories in the genome engineering field. The customized endonucleases developed on our engineering platform are optimized for high target specificity and low cellular toxicity, and the lead therapeutic candidates we have generated are directed to cancer and infectious disease targets.
Company Details
- Employees
- 2
- Address
- 454 N 34th St, Seattle,wa 98103-8602,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.bluebirdbio.com/
- Keywords
- gene therapy, cell-based therapeutics, homing endonucleases, cancer therapeutics, infectious disease therapeutics, genome engineering, custom enzyme engineering.
- HQ
- Seattle, WA
Pregenen Questions
Pregenen's website is http://www.bluebirdbio.com/
Pregenen's LinkedIn profile is https://www.linkedin.com/company/pregenen
Pregenen has
2 employees.
View email and phone details for 2
employees at Pregenen.
Pregenen's industry is
Biotechnology Research
Pregenen's categories are Biotechnology Research
